Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents

Reinier Cornelis Anthonius van Linschoten*, Elyke Visser, Christa Diana Niehot, C. Janneke van der Woude, Jan Antonius Hazelzet, Desirée van Noord, Rachel Louise West

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

45 Citations (Scopus)

Abstract

Background: Knowledge of the cost of illness of inflammatory bowel disease (IBD) is essential for health policy makers worldwide. Aim: To assess the cost of illness of IBD from the societal perspective taking into account time trends and geographical differences. Methods: A systematic review of all population-based studies on cost of illness of IBD published in Embase, Medline, Web of Science and Google Scholar. Methodology of included studies was assessed and costs were adjusted to 2018 US dollars. Results: Study methodologies differed considerably, with large differences in perspective, valuation method and population. For prevalent Crohn's disease (CD) cases in the last ten years annual healthcare costs were in Asia $4417 (range $1230-$31 161); Europe $12 439 ($7694-$15 807) and North America $17 495 ($14 454-$20 535). For ulcerative colitis (UC), these were $1606 ($309-$14 572), $7224 ($3228-$9779) and $13 559 ($13 559-$13 559). The main cost driver was medication, the cost of which increased considerably between 1985 and 2018, while outpatient and inpatient costs remained stable. IBD had a negative impact on work productivity. Annual costs of absenteeism for CD and UC were in Asia (with presenteeism) $5638 ($5638-$5638) and $4828 ($4828-$4828); Europe $2660 ($641-$5277) and $2394 ($651-$5992); North America $752 ($307-$1303) and $1443 ($85-$2350). Conclusion: IBD societal cost of illness is increasing, driven by growing costs of medication, and varies considerably between continents. While biologic therapy was expected to decrease inpatient costs by reducing hospitalisations and surgery, these costs have not declined.

Original languageEnglish
Pages (from-to)234-248
Number of pages15
JournalAlimentary Pharmacology and Therapeutics
Volume54
Issue number3
DOIs
Publication statusPublished - 11 Jun 2021

Bibliographical note

Funding Information:
Drs. van Linschoten, Drs. Visser, Prof. Dr. Hazelzet and Drs. Niehot have nothing to disclose. Prof. Dr. van der Woude reports personal fees from Abbvie and Celltrion, and grants from Pfizer and Janssen outside the submitted work. Dr. van Noord reports grants from AbbVie, Falk, Ferring, Janssen, MSD, Pfizer, and Takeda and personal fees from Takeda and Janssen outside the submitted work. Dr. West reports grants from AbbVie, Falk, Ferring, Janssen, MSD, Pfizer, and Takeda and personal fees from AbbVie, Janssen, and Pfizer outside the submitted work. Declaration of personal interests:

Publisher Copyright:
© 2021 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.

Fingerprint

Dive into the research topics of 'Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents'. Together they form a unique fingerprint.

Cite this